Clinical study of Jiawei Yanghe Decoction in the treatment of peripheral arterial disease
DAI Dandan1 SUI Wenlin1 LI Meiyu2
1.Drug Manufacturing Room, Liaoyang Hospital of Traditional Chinese Medicine, Liaoning Province, Liaoyang 111000, China;
2.Department of Geriatrics, Liaoyang Hospital of Traditional Chinese Medicine, Liaoning Province, Liaoyang 111000, China
Abstract：Objective To investigate the clinical effect of Jiawei Yanghe Decoction treating peripheral arterial disease(PAD). Methods A total of 133 PAD patients in Liaoyang Hospital of Traditional Chinese Medicine were selected from March 2017 to March 2019 and they were divided into the study group (67 cases, conventional western medicine combined with Jiawei Yanghe Decoction) and the control group (66 cases, conventional western medicine) according to the random number table method. The clinical efficacy, adverse reactions, traditional Chinese medition syndrome score, hemorheology indexes and ankle brachial index (ABI), blood flow of dorsalis pedis artery and intermittent claudication distance of patients in the two groups were compared. Results After treatment the total clinical effective rate of the study group was higher than that of the control group (P ＜ 0.05). After 1 month of treatment, the traditional Chinese medition syndrome scores and high blood viscosity, plasma viscosity, hematocrit, red cell assembling index in the two groups were all lower than before treatment, and the study group was lower than the control group (P ＜ 0.05). After 1 month of treatment, the ABI, blood flow of dorsalis pedis artery, intermittent claudication distance were increased in the two groups, and the study group was higher than the control group (P ＜ 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion Jiawei Yanghe Decoction can rapidly improve the clinical symptoms of patients with PAD, with definite curative effect, and also can improve the blood circulation of the body, with good drug safety.
代丹丹1 隋文林1 李美彧2. 加味阳和汤治疗下肢动脉硬化闭塞症的临床研究[J]. 中国医药导报, 2020, 17(7): 152-155.
DAI Dandan1 SUI Wenlin1 LI Meiyu2. Clinical study of Jiawei Yanghe Decoction in the treatment of peripheral arterial disease. 中国医药导报, 2020, 17(7): 152-155.
[1] Blessing E，Lugenbiel I，Holden A. The evidence to support the use of focal force balloon technology to improve outcomes in the treatment of lower extremity arterial occlusive disease [J]. J Cardiovasc Surg（Torino），2019，60（1）：14-20.
[2] Society for Vascular Surgery Lower Extremity Guidelines Writing Group，Conte MS，Pomposelli FB，et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lowerextremities： management of asymptomatic disease and claudication [J]. J Vasc Surg，2015，61（3 Suppl）：2S-41S.
[3] Espinola-Klein C. Anti-Thrombotic Treatment of Patients with Peripheral Artery Disease （PAD）[J]. Dtsch Med Woc-henschr，2018，143（15）：1060-1064.
[4] 孙旭，张立民.下肢动脉硬化闭塞症的中医认识[J].安徽中医药大学学报，2017，36（6）：8-10.
[5] 石光煜，黄艳洪，张百亮，等.阳和汤加味治疗下肢动脉硬化闭塞症35例临床观察[J].中国中医药科技，2016， 23（1）：75-76.
[6] 刘昌伟.下肢动脉硬化性闭塞症治疗指南[J].中国实用外科杂志，2008，27（11）：923-924.
[7] 李灿东.中医诊断学[M].北京：中国中医药出版社，2012：245-263.
[8] 郑筱萸.中药新药临床研究指导原则（试行）[M].北京：中国医药科技出版社，2002：346-349.
[9] 师天雄，缪健航，胡锡祥.下肢动脉硬化性闭塞症的介入治疗体会[J].中国普外基础与临床杂志，2010，17（7）：676-678.
[10] 赵战芝，姜志胜.我国动脉粥样硬化基础研究几个热点领域的新进展[J].中国动脉硬化杂志，2019，27（8）：645-654.
[11] 田珂，常超.经皮腔内血管成形术/支架植入术联合瑞舒伐他汀治疗下肢动脉硬化闭塞症远期疗效分析[J].中华实验外科杂志，2019，36（1）：175-176.
[12] Shammas NW. Commentary：Treating subacute thrombus in peripheral arterial disease：the effectiveness of ultrasound-accelerated lysis [J]. J Endovasc Ther，2015，22（1）：96-98.
[13] Jongsma H，Bekken JA，de Vries JP，et al. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty in patients with femoropopliteal arterial occlusive disease [J]. J Vasc Surg，2016，64（5）：1503-1514.
[14] Yong J，Wang Y，Xing S，et al. Efficacy of trimetazidine and plasmin combined with alprostadil in treatment of lower extremity arteriosclerosis obliterans [J]. Exp Ther Med，2019，17（6）：4554-4560.
[15] 艾明瑞，冉宪俊，王玉玲，等.阳和健脾汤联合西洛他唑治疗下肢动脉硬化闭塞症的临床效果及安全性分析[J].解放军医药杂志，2019，31（6）：87-90.
[16] 刘亚莉，李友山，杨博华，等.数据挖掘庞鹤教授辨治下肢动脉硬化闭塞症的用药规律[J].中国医药导报，2018， 15（33）：102-105，125.
[17] 曹端广，夏汉庭，杨文龙，等.加味阳和汤对肾阳虚型骨质疏松模型大鼠骨密度及血清微量元素的影响[J].安徽中医药大学学报，2019，38（3）：76-79.
[18] 张毅鹏.加味阳和汤防治奥沙利铂周围神经毒性的临床观察[J].中国现代医生，2018，56（15）：124-126.
[19] Kim M，Kim JU，Kim SM，et al. Effectiveness of beraprost sodium in maintaining vascular access patency in patients on hemodialysis [J]. Int Urol Nephrol，2017，49（7）：1287-1295.
[20] 王芸.加味阳和汤配合骨盆牵引治疗急性腰椎间盘突出症临床观察[J].中国中医急症，2013，22（10）：1781-1782.
[21] 陈波，马军，王海涛，等.介入技术在下肢动脉硬化闭塞症合并血栓形成中的应用[J].现代生物医学进展，2016，16（2）：275-277.
[22] 苏虹虹，郭笑盈.评估踝臂指数在下肢动脉硬化闭塞症介入治疗中的临床价值[J].中国医药科学，2018，8（19）：227-230.
[23] 王文波，董建文，杨振国，等.加味阳和汤对早期膝骨关节炎兔关节软骨的影响[J].中医正骨，2015，27（1）：1-4.
[24] 张芳，闫海洋，陈旭义，等.淫羊藿苷对微重力下骨髓间充质干细胞增殖与凋亡的影响[J].中国医药导报，2018，15（1）：10-13，21.
[25] 程志清，黄建平，朱文宗，等.淫羊藿苷脂质体经鼻给药对帕金森病大鼠行为学及神经递质的影响[J].中国现代医生，2019，57（19）：43-47，封3.
2020, Vol. 17 
京公网安备 11010502046598号